Shots:

• Amgen has consummated the purchase of Astellas’49% shares of AABP- a JV between Amgen and Astellas established in 2013
• AABP now serves as a wholly-owned Amgen affiliate in Japan while the Amgen renamed it as Amgen KK- enabling the company to bolster its presence in Japan
• Amgen KK will continue the marketing of therapies targeting CV- cancer- osteoporosis and will bring Amgen’s global pipeline to Japanese patients. Additionally- in 2019- Amgen has invested ~$4B in research and development to advance new therapies across all stages of its pipeline

Click here ­to­ read full press release/ article | Ref: Amgen | Image: Behance